November 20, 2023

UCB CEO visits bonded area to boost biopharmaceutical industry

Recently, Jean-Christophe Tellier, the CEO of UCB, visited the bonded area and had a special discussion with the management bureau of the bonded area.

UCB is a global biopharmaceutical company headquartered in Belgium, focusing on developing innovative drugs and therapies for severe diseases of the immune and nervous systems. Currently, UCB has about 7,500 employees worldwide, and its business covers 40 countries and regions around the world.

In 2006, UCB established UCB Trading (Shanghai) Co Ltd in the Waigaoqiao Bonded Area, mainly engaged in the sales of nervous system and immune system drugs.

Zhang Xi, the director of the management bureau of the bonded area, pointed out that in recent years, the bonded area has attached great importance to the high-quality development of the regional biopharmaceutical industry and bio-pharmaceutical enterprises such as UCB.

The bonded area has continuously innovated in systems, policies and services, actively creating a soil suitable for the innovative development of bio-pharmaceutical enterprises, and the industrial scale has maintained continuous growth.

In the first three quarters of this year, the import value of medical instruments and equipment in the region was 31.68 billion yuan (US$4.37 billion), a year-on-year increase of 9.4 percent, and the proportion of the import value of similar goods in the country increased by 3.1 percentage points to 43.4 percent compared with last year.

The import value of drugs was 73.86 billion yuan, a year-on-year increase of 23.2 percent, and the proportion of the import value of drugs in the country increased by 6 percentage points to 26.8 percent.

Tellier said that in recent years, the achievements of the bonded area in the economy and biopharmaceutical industry have made him confident about the company's future development in China. UCB will help more Chinese companies with globalization ambitions expand overseas markets, and at the same time, further increase investment in the Chinese market, bring more business, global-leading technology and products to China to benefit more patients.